{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-053509","form_type":"8-K","ticker":"MRKR","cik":"0001094038","company_name":"Marker Therapeutics, Inc.","filed_at":"2023-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.922591+00:00","generated_at":"2026-06-16T04:37:30.891311+00:00","sec_items":["1.01","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Marker Therapeutics sells manufacturing assets for $19M, appoints Juan Vera as CEO, extends runway to end of 2025","bullets":["CellReady to purchase Marker's manufacturing assets for ~$19M in cash; annual overhead reduced by ~$11M; closing targeted June 26, 2023.","CEO Peter Hoang resigns effective May 1; board appoints Juan Vera (formerly COO/CSO) as President and CEO.","Non-dilutive deal extends Marker's financial runway through year-end 2025; net benefit estimated at ~$42M.","Clinical priorities: MT-601 in NHL trial, MT-401 in post-transplant AML; data expected H2 2024.","Board member David Laskow-Pooley will not stand for reelection at 2023 annual meeting, term expires then."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-053509","json":"https://secwatch.observer/filing/0001104659-23-053509.json","markdown":"https://secwatch.observer/filing/0001104659-23-053509.md","text":"https://secwatch.observer/filing/0001104659-23-053509.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923053509/0001104659-23-053509-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923053509/tm2314110d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T04:37:30.891311+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"07e8405c48","claim":"Juan Vera was appointed as President and Chief Executive Officer at Marker Therapeutics, Inc..","evidence_excerpt":"On April 27, 2023, the Board appointed Juan Vera as the Company’s President and Chief Executive Officer, effective as of the effective time of Mr. Hoang’s resignation.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923053509/0001104659-23-053509-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"60f4e0c1d9","claim":"Peter Hoang resigned as President and Chief Executive Officer at Marker Therapeutics, Inc..","evidence_excerpt":"On April 27, 2023, Peter Hoang, the Company’s President and Chief Executive Officer, resigned from his operating role, effective May 1, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923053509/0001104659-23-053509-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"84c566a425","claim":"David Laskow-Pooley departed as Director at Marker Therapeutics, Inc..","evidence_excerpt":"On April 27, 2023, Mr. David Laskow-Pooley, a member of the Board, notified the Board that he will not stand for reelection as a director of the Company upon expiration of his current term.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923053509/0001104659-23-053509-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"not stand for reelection"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"b6e07dcf7d","claim":"Peter Hoang resigned as Director at Marker Therapeutics, Inc..","evidence_excerpt":"Mr. Hoang also resigned as a member of the Company’s Board of Directors (the “ Board ”), effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923053509/0001104659-23-053509-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"96c76edd56025b1c4c6fa658b245aecd4f1a4734","claim":"Marker Therapeutics, Inc. entered into Purchase Agreement with Cell Ready, LLC valued at approximately $19.0 million (effective 2023-05-01).","evidence_excerpt":"On May 1, 2023, Marker Therapeutics, Inc. (the “ Company ”) entered into a purchase agreement (the “ Agreement ) with Cell Ready, LLC (“ Cell Ready ”), pursuant to which the Company will (i) assign to Cell Ready the leases for the Company's two manufacturing facilities in Houston, Texas (the “ Manufacturing Facilities ”), (ii) sell to Cell Ready all of the equipment and leasehold improvements at the Manufacturing Facilities and (iii) assign to Cell Ready its rights, title and interest in the Company's Master Services Agreement for Product Supply, dated April 7, 2023, by and between the Company, Cell Ready and Indapta Therapeutics, Inc., as well as its rights, title and interest in any contracts related to the equipment and Manufacturing Facilities (collectively, the “ Purchased Assets ”). Pursuant to the Agreement, Cell Ready will acquire the Purchased Assets for total consideration of approximately $19.0 million. In connection with the purchase of the Manufacturing Facilities, Cell Re","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923053509/0001104659-23-053509-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Cell Ready, LLC"},{"label":"Value","value":"approximately $19.0 million"},{"label":"Effective","value":"2023-05-01"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}